United States - English - NLM (National Library of Medicine)

octapharma usa inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - panzyga is indicated for treatment of primary humoral immunodeficiency (pi) in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. panzyga is indicated for the treatment of adult patients with itp to raise platelet counts to control or prevent bleeding. panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. - panzyga is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin. - panzyga is contraindicated in iga-deficient patients with antibodies against iga and history of hypersensitivity . risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - panzyga is indicated for treatment of primary humoral immunodeficiency (pi) in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. panzyga is indicated for the treatment of adult patients with itp to raise platelet counts to control or prevent bleeding. panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. - panzyga is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin. - panzyga is contraindicated in iga-deficient patients with antibodies against iga and history of hypersensitivity . risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted

United States - English - NLM (National Library of Medicine)

octapharma usa inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - panzyga is indicated for treatment of primary humoral immunodeficiency (pi) in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. panzyga is indicated for the treatment of adult patients with itp to raise platelet counts to control or prevent bleeding. panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. - panzyga is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin. - panzyga is contraindicated in iga-deficient patients with antibodies against iga and history of hypersensitivity . risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin (human) - solution - 100mg - immunoglobulin (human) 100mg - serums

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma ag, switzerland - human immunoglobulin proteins - solution for infusion - 100 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma ag, switzerland - human immunoglobulin proteins - solution for infusion - 100 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma ag, switzerland - human immunoglobulin proteins - solution for infusion - 100 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma ag, switzerland - human immunoglobulin proteins - solution for infusion - 100 mg/ml